Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of “Hold” by Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been given an average rating of “Hold” by the ten research firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.79.

Separately, StockNews.com began coverage on shares of Marinus Pharmaceuticals in a research note on Monday, May 5th. They issued a “sell” rating on the stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $0.55 on Tuesday. The firm’s 50-day moving average is $0.55 and its 200-day moving average is $0.47. The stock has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $1.97.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Marinus Pharmaceuticals during the fourth quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals during the fourth quarter worth $54,000. Deltec Asset Management LLC acquired a new stake in Marinus Pharmaceuticals in the fourth quarter worth $107,000. XTX Topco Ltd grew its holdings in Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares during the period. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.